Clinical trials: Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
- Condition Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
- Funder type Industry (pharma, biotech, devices)
Catecholaminergic Polymorphic Ventricular Tachycardia
Safety, Tolerability, and Exploratory Efficacy of AGP100 in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
This trial is conducted in patients with an inherited heart rhythm disorder called catecholaminergic polymorphic ventricular tachycardia (CPVT).
- Trial name
- NCT07263139
- Testing
- AGP100
- Where
- Norway
- Volunteers
- 10 people
- Sponsor
- Agiana Pharmaceuticals
Catecholaminergic Polymorphic Ventricular Tachycardia
A Phase 2 Study of CRD-4730 in CPVT
This is a Phase 2, multicenter, double-blind, sponsor blinded, placebo-controlled, repeat-dose clinical study of CRD-4730 to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of CRD-4730 to…
- Trial name
- CPVT (NCT06658899)
- Testing
- CRD-4730
- Where
- 12 sites in United States, Canada and 4 more
- Volunteers
- 12 people
- Sponsor
- Cardurion Pharmaceuticals, Inc.
Catecholaminergic Polymorphic Ventricular Tachycardia
A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
This is a Phase 1b, Multicenter, Open-Label, Dose Finding Study to Investigate the Safety and Tolerability of a Single Intravenous Dose of SGT-501 in participants with catecholaminergic polymorphic ventricular tachycardia (CPVT).
- Trial name
- ARTEMIS (NCT07148089)
- Testing
- SGT-501
- Where
- 5 sites in United States, Canada
- Volunteers
- 18 people
- Sponsor
- Solid Biosciences Inc.
CPVT1, Heart Defects, Congenital
Effectiveness of CRD-4730 in Participants With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
This is a Phase 2, multicenter, double-blind, sponsor unblinded, placebo-controlled, single-dose clinical study of CRD-4730 to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of CRD-4730 when…
- Conditions
- CPVT1, Heart Defects, Congenital, Heart Diseases, Ventricular Tachycardia
- Trial name
- CPVT (NCT06005428)
- Testing
- CRD-4730
- Where
- 11 sites in United States, Canada and 2 more
- Volunteers
- 7 people
- Sponsor
- Cardurion Pharmaceuticals, Inc.